Annexin: Preclinical progress with ANXV conjugate - Redeye

Redeye endorses today’s news that Annexin has reported preclinical progress with its approach to use ANXV as a drug conjugate, ie to deliver a chemotherapy agent specifically to the tumor with the goal to achieve a similar or better effect with reduced side effects. In today’s statement, the company reports that it has successfully produced a conjugate that also has been tested with initial promising results. While early, we are encouraged to see progress with this approach and hope to learn more about the way forward soon.

Länk till analysen i sin helhet: https://www.redeye.se/research/945393/annexin-preclinical-progress-with-anxv-conjugate?utm_source=finwire&utm_medium=RSS